Sara Gandini
The Molecular and Pharmaco-Epidemiology Unit conducts interdisciplinary research at the intersection of epidemiology, biostatistics, translational oncology and clinical research, with the goal of advancing cancer prevention, precision oncology and evidence-based medicine.
The Unit combines population-based studies, clinical trials, real-world evidence, biomarker research and advanced statistical methodologies to investigate cancer risk, prognosis and treatment response. A distinctive strength is the application of rigorous methodological approaches to study design, causal inference, evidence synthesis and predictive modeling, ensuring that research findings are robust, reproducible and clinically relevant. Our work also critically evaluates emerging technologies, including artificial intelligence and radiomics, promoting their responsible integration into clinical practice through methodological validation.
Research activities focus on cancer prevention, molecular and pharmaco-epidemiology, lifestyle and environmental risk factors, genetic susceptibility, microbiome, metabolomics, and imaging biomarkers. By integrating clinical, epidemiological, molecular and multi-omics data, we develop personalized strategies for cancer prevention, early detection and precision medicine.
Through national and international collaborations, the Unit contributes to generating high-quality evidence that informs clinical decision-making, public health policies and the development of innovative prevention and treatment strategies, with the ultimate aim of improving patient outcomes.
READ MORE
